[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hematology department of the 920th hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,65,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100054233","phase-2-dexamethasone-intravenous-injection-of-human-immunoglobulin-and-increased-infusion-of-mononuclear-cells-to-reduce-donor-specific-antibodies-in-haploid-hematopoietic-stem-cell-transplantation-a-prospective-multicenter-study-100054233",false,"NCT07698080","Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploid Hematopoietic Stem Cell Transplantation: a Prospective, Multicenter Study","Inclusion Criteria:\n\n1. Diagnosis of benign or malignant hematological diseases (including leukemia, lymphoma, thalassemia, aplastic anemia, myelodysplastic syndromes, etc.) confirmed by NCCN guidelines, and determined by the investigator to require allogeneic hematopoietic stem cell transplantation.\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n3. Donor-specific antibody (DSA) mean fluorescence intensity (MFI) \\> 500.\n4. Age between 18 and 65 years (age limits are also captured separately in the eligibility module).\n5. Body weight between 40 kg and 100 kg.\n6. No other suitable donor available (i.e., no DSA-negative related donor or unrelated donor).\n\nExclusion Criteria:\n\n1. Patients unsuitable for transplantation or without willingness to undergo transplantation, or diagnosed with non-hematological diseases.\n2. Estimated life expectancy \\\u003C 1 month.\n3. Known allergy to any drug or intervention used in the study regimen.\n4. Pregnancy, lactation, active severe infection, or severe major organ dysfunction.\n5. Severe psychiatric or neurological disorders that may affect the ability to provide informed consent and\u002For to report adverse events or comply with observation.\n6. Refusal or inability to sign the informed consent form.","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study tests whether a combination of three treatments - dexamethasone (a steroid), intravenous immunoglobulin (IVIG, a protein that helps the immune system), and an extra dose of donor mononuclear cells - can safely lower harmful antibodies called donor-specific antibodies (DSA) in patients who need a stem cell transplant from a half-matched (haploidentical) family donor.\n\nIn these transplants, DSA are antibodies made by the patient's own body that attack the donor's stem cells. If DSA levels are high, the transplant is more likely to fail - the donor cells may not \"take\" (engraft). Currently, there is no single, simple, and reliable way to reduce DSA, and many existing methods have drawbacks.\n\nBased on our earlier experience in 11 patients, this three-part approach seemed to work well. All patients successfully engrafted, and DSA levels dropped quickly. Now we want to confirm these results in a larger, prospective, multicenter study.\n\nWe plan to enroll 60 patients aged 18-65 with blood cancers or other blood disorders who need a haploidentical transplant, have DSA levels above 500 MFI (a measure of antibody strength), and have no other suitable donor available. Participants will receive:\n\n* Dexamethasone (25 mg\u002Fm²) for 4 days before transplant,\n* IVIG (1 g\u002Fkg) one day before transplant,\n* Extra mononuclear cells on transplant day - the extra amount depends on how high their DSA level is (low, medium, or high).\n\nThe main goal is to see how many patients have primary graft failure (when the donor cells never engraft). We will also measure how long it takes for blood counts to recover, rates of graft-versus-host disease, survival, and side effects. All participants will be followed for 1 year.\n\nThis study will help us find out whether this combination is a safe, simple, and effective way to improve transplant success for patients with DSA who have no other donor options.",[26,27,28,29,30],"Leukemia","Lymphoma","Thalassemia","Aplastic Anemia","Myelodysplastic Syndromes","NOT_YET_RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":20},"2026-07-03",{"date":39,"type":20},"2028-07-03",{"name":41,"class":42},"Hematology department of the 920th hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100643248","phase-2-va-cag-two-week-vs-three-week-regimen-for-induction-remission-in-newly-diagnosed-acute-myeloid-leukemia-100643248","NCT07642453","VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.","VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Diagnosis of acute myeloid leukemia confirmed according to NCCN guidelines;\n2. Age 18-75 years;\n3. Body weight 30-100 kg;\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3;\n5. No significant organ dysfunction (echocardiographic ejection fraction \\>45%; bilirubin \\\u003C2 times the upper limit of normal; AST and ALT \\\u003C3 times the upper limit of normal; serum creatinine \\\u003C2 times the upper limit of normal);\n6. No severe infections;\n7. Study participants voluntarily agree to participate in this clinical trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other types of diseases;\n2. Patients with a projected survival of less than 1 month;\n3. History of prior treatment;\n4. Severe psychiatric or neurological disorders that impair the ability to provide informed consent and\u002For report or observe adverse events;\n5. Other circumstances deemed unsuitable for enrollment by the investigator.","75 Years",{"count":52,"type":20},110,[23],"Objective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML).\n\nKey Research Questions:\n\n1. Is the efficacy of the two-week VA-CAG regimen equivalent to that of the three-week regimen in inducing remission in AML?\n2. Does the two-week VA-CAG regimen reduce treatment-related adverse events compared to the three-week regimen? Methods: Researchers will compare the efficacy and safety of the two-week VA-CAG regimen with the three-week regimen for induction remission in AML. Study participants will be randomly assigned to receive standard treatment with either the two-week or three-week VA-CAG regimen. Patients are required to attend monthly follow-up visits for a total of one year. At each follow-up, the following assessments will be performed: complete blood count, liver and kidney function tests, bone marrow aspiration, flow cytometric measurement of minimal residual disease (MRD), and\u002For fusion gene analysis, along with monitoring of other efficacy endpoints and adverse reactions.",[56],"Acute Myeloid Leukemia (AML)","2026-06-07",{"date":59,"type":35},"2026-06-11",{"date":61,"type":20},"2026-06-01",{"date":63,"type":20},"2028-06-01",{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100552681","risk-factors-for-postoperative-cough-in-patients-undergoing-thoracoscopic-lung-resection-100552681","NCT06476249","Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection","A Prospective Cohort Study on Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection","Inclusion Criteria:\n\n● Patients aged 18 years or older and less than or equal to 70 years of age who underwent surgery with video-assisted thoracoscopic pneumonectomy.\n\nExclusion Criteria:\n\n* Pre-existing cough before surgery (e.g. asthma, taking ACEI Drugs, etc.)\n* Distant metastasis of tumor\n* Combined pregnancy or breastfeeding\n* Combined with other systemic major diseases (such as malignant swelling, chronic liver insufficiency, chronic renal insufficiency, etc.)\n* Suffering from mental illness\n* Refusal of follow-up or incomplete clinical information\n* Poor compliance and other groups considered by the investigator not suitable for inclusion","70 Years",{"count":74,"type":20},1000,"OBSERVATIONAL","Lung cancer, as the main cause of cancer-related deaths in both males and females, is a great risk to human health. Pulmonary resection is the most applicable to early-stage lung cancer diagnoses and considered the best curative options. Coughing is a prominent symptom among postoperative complications, with approximately 18%-50% of patients experiencing persistent coughing after surgery. This study is a prospective observational study and is expected to be carried out in a large tertiary hospital. This cohort is expected to include 1000 participants for three years.\n\nPatients with pulmonary nodules on chest CT will be divided into two groups based on the presence or absence of cough symptoms on admission. The investigators decided whether to include patients in this cohort study strictly based on the inclusion and exclusion criteria. The severity of cough, the trajectory of cough change, and the physiological and social burden caused by cough will be reflected by the results of LCQ-MC, CSS, HARQ, and VAS. LCQ-MC, CSS, HARQ, and VAS are just a few of the questionnaires that are widely used to investigate the cough and severity of the respondent. The included variables included age, gender, Height, Weight, education level, smoking history, alcohol history, preoperative lung function, nodule size, preoperative and postoperative blood routine (such as white blood cell count, neutrophil count, etc.), blood biochemistry (such as C-reactive protein, PCT, etc.), liver and kidney function test results, surgical method, surgical site, operation duration, anesthesia method, anesthesia duration, lymph node dissection, pathological results, chest tube caliber, number of days of catheterization, use of cough drugs, use of non-steroidal anti-inflammatory drugs, Number of days in hospital and number of outpatient visits due to cough.",[78],"Lung Cancer",[80,81],"cough after pulmonary resection","thoracoscopic lung resection","RECRUITING","2024-06-26",{"date":85,"type":35},"2024-06-28",{"date":87,"type":35},"2024-03-01",{"date":89,"type":20},"2027-05-01",{"name":41,"class":42},1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":15,"minAge":100,"maxAge":17,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":91},"100545143","phase-2-clinical-study-on-modified-allogeneic-hematopoietic-stem-cell-transplantation-regimen-for-severe-aplastic-anemia-100545143","NCT06378060","Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia","A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of a Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia","Inclusion Criteria:\n\n1. Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring allogeneic hematopoietic stem cell transplantation as determined by the researchers;\n2. Age 3-65 years old;\n3. Weight 10Kg-100Kg;\n4. Eastern Cooperative Oncology Group (ECOG) score ≤3;\n5. No major organ injury (ECG ejection fraction \\>45%; bilirubin \\\u003C 2 times the upper limit of normal value; AST and ALT \\\u003C 3 times the upper limit of normal value; serum creatinine \\\u003C 2 times the upper limit of normal value);\n6. No severe infection;\n7. Subjects voluntarily participated in this clinical trial and signed the informed consent.\n\nExclusion Criteria:\n\n1. patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;\n2. patients with an expected survival of less than 1 month;\n3. patients with previous autologous or allogeneic hematopoietic stem cell transplantation;\n4. pregnant patients;\n5. patients with severe mental or neurological disorders that would affect the ability to provide informed consent and\u002For to report or observe adverse events;\n6. other conditions that the investigator determines to be inappropriate for enrollment.",true,"3 Years",{"count":102,"type":20},30,[23],"The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.",[106],"Severe Aplastic Anemia",[106,108,109,110],"Modified transplantation system","Ruxolitinib","Melphalan","2024-04-19",{"date":113,"type":35},"2024-04-22",{"date":87,"type":35},{"date":116,"type":20},"2027-04-01",{"name":41,"class":42},""]